SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-102289
Filing Date
2022-04-12
Accepted
2022-04-12 06:06:03
Documents
13
Period of Report
2022-05-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A d301043ddef14a.htm DEF 14A 437265
2 GRAPHIC g301043dsp001.jpg GRAPHIC 226056
3 GRAPHIC g301043dsp002.jpg GRAPHIC 144804
4 GRAPHIC g301043g10o34.jpg GRAPHIC 27019
5 GRAPHIC g301043g11i11.jpg GRAPHIC 26057
6 GRAPHIC g301043g15g55.jpg GRAPHIC 26545
7 GRAPHIC g301043g22i22.jpg GRAPHIC 26232
8 GRAPHIC g301043g33i33.jpg GRAPHIC 25624
9 GRAPHIC g301043g35z31.jpg GRAPHIC 24028
10 GRAPHIC g301043g44i44.jpg GRAPHIC 24536
11 GRAPHIC g301043g49q08.jpg GRAPHIC 107122
12 GRAPHIC g301043g57t78.jpg GRAPHIC 51485
13 GRAPHIC g301043g69o10.jpg GRAPHIC 38750
  Complete submission text file 0001193125-22-102289.txt   1436863
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36510 | Film No.: 22821039
SIC: 2834 Pharmaceutical Preparations